Tamoxifen case on Endometrial Adenocarcinoma (MCQ)
Check your answer ...
Tamoxifen has a stimulatory effect on the endometrium, leading to an increased risk of developing
endometrial hyperplasia and eventually endometrial carcinoma.
Tamoxifen is a selective estrogen receptor modulator (SERM) used in the treatment of estrogen
receptor positive breast cancer.
Tamoxifen is an estrogen agonist in endometrial tissue but an estrogen antagonist in the
breast. Therefore, while tamoxifen antagonist activity in the breast makes it an effective agent in the
treatment breast cancer, its agonist effect in the endometrial tissue of the uterus can lead to
excessive endometrial stimulation.
A benefit of the estrogenic activity of tamoxifen in bone is an increase in bone mineral density, making
tamoxifen a useful agent in the treatment of osteoporosis.